|WFI water nebulization Wiki
|inhaled type I interferon Wiki
There are 2 clinical trials
In light of its high morbidity and mortality, COronaVIrus Disease 19 (COVID-19) pandemic spread is considered an unprecedented global health challenge. Given the very limited therapeutic options available against Severe Acute Respiratory Syndrome - CoronaVirus-2 (SARS-CoV-2) epidemic at this time, the evaluation of new resources, designed in the first instance for other pathologies but potentially active against COVID-19, represents a priority in clinical research. This is an observational, retrospective, non-profit study on the adjuvant use of bacteriotherapy in the early control of disease progression in patients affected by COVID-19 and treated with the current standard of care on the basis of the interim guidelines of the Italian Society of Infectious and Tropical Diseases. The main purpose of the study is to evaluate the effectiveness of bacteriotherapy in reducing the clinical impact of acute diarrhea, containing the progression of COVID-19 and preventing the need for hospitalization in intensive care units.
Description: Comparison between the two groups. Acute diarrhea was defined as a stool with increased water content, volume, or frequency that lasts less than 14 days.Measure: delta of time of disappearance of acute diarrhea Time: 21 days
Description: Comparison between the two groupsMeasure: Delta in the number of patients requiring orotracheal intubation despite treatment Time: 21 days
Description: Comparison between the two groupsMeasure: Delta of crude mortality Time: 21 days
Description: Comparison between the two groupsMeasure: Delta of length of stay for patients in hospital Time: 21 days
The present study conducted to correlate symptoms not only constitutional and respiratory, but GIT as a principle presentation, with laboratory markers and COVID-19 severe acute respiratory syndrome (SARS-COV2) disease outcomes, as the duration of symptoms varies substantially between patients; the investigators undertook this study to determine the optimal time to predict COVID-19 outcomes based on real-time experience.
Description: The investigators tried to correlate disease severity with disease durationMeasure: COVID-19 disease spectrum and duration Time: july 2020 to june 2020
Description: spectrum of GIT manifestations in COVID-19 patients was investigatedMeasure: GIT manifestations among COVID-19 patients Time: july 2020 to june 2020
Description: The link between non-communicable disease (including diabetes, hypertension and Hypercholesterolemia) severity and COVID-19 prognosisMeasure: Non-communicable disease and COVID-19 Time: july 2020 to june 2020
Description: the investigators studied the Impact of weather climate on COVID-19 presentations (higher incidence of diarrhea in COVID-19 patients in summer) and outcomesMeasure: Seasonal change and COVID-19 Time: july 2020 to june 2020
Description: The investigators tried to find new Egyptian classification fro COVID-19 disease severityMeasure: Possible region specific classification for COVID-19 disease Time: july 2020 to june 2020
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports